Growth and scale Pharos Capital Group is a physician-founded investment firm focused on growing healthcare companies with over $900 million AUM and a history of investing in mid-market healthcare platforms. This suggests opportunities to discuss strategic add-ons, co-investment, or recapitalization needs from portfolio companies seeking scale.

Healthcare focus Current and past investments include post-acute care, renal services, dialysis, and health services platforms, signaling readiness to engage with portfolio companies on exits, performance improvement initiatives, or funding for expansion, acquisitions, or telemedicine enhancements.

Executive accessibility Recent hire of Alice Rhee as Head of Investor Relations and Social Impact indicates an emphasis on stakeholder communication and ESG/social impact storytelling, presenting an opening to propose investor relations support, impact metrics packages, or co-led fundraising conversations.

Active exits Notable strategic exit activity in early 2023 with the sale of Motion PT Group to Confluent Health demonstrates a track record of value realization, suggesting opportunities to explore recapitalizations, secondary sales, or positioning for portfolio company exits.

Platform expansion Portfolio diversification includes platform acquisitions such as Providence Home Health and Hospice and Sanderling Renal Services, indicating ongoing growth through bolt-ons; sales conversations could target proprietary deal sourcing, integration services, and operating improvements for add-on acquisitions.